Analysts expect Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) to report $-0.16 EPS on March, 5.They anticipate $0.17 EPS change or 1,700.00% from last quarter’s $0.01 EPS. After having $-0.07 EPS previously, Cumberland Pharmaceuticals Inc.’s analysts see 128.57% EPS growth. The stock increased 0.35% or $0.02 during the last trading session, reaching $5.66. About 1,262 shares traded. Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) has declined 13.55% since February 15, 2018 and is downtrending. It has underperformed by 13.55% the S&P500. Some Historical CPIX News: 11/04/2018 – Rhode Island DoA: Cumberland Technical Review Committee Wed, 4/11/2018, 11:00 AM; 23/04/2018 – Rhode Island DoA: Cumberland Public Library Board of Trustees Mon, 4/23/2018, 6:30 PM; 13/04/2018 – Rhode Island DoA: Cumberland Fire District – Finance Committee Sat, 4/14/2018, 10:00 AM; 18/04/2018 – Rhode Island DoA: Cumberland Town Council Wed, 4/18/2018, 8:30 PM; 16/03/2018 – CUMBERLAND PHARMACEUTICALS SAYS IS NOW RESPONSIBLE FOR MAINTAINING FDA APPROVAL AND FOR OVERSEEING OMECLAMOX((REG))-PAK ‘S PACKAGING – SEC FILING; 07/03/2018 – Rhode Island DoA: Cumberland Charter Review Commission Wed, 3/7/2018, 6:30 PM; 21/03/2018 – Rhode Island DoA: Cumberland Finance Sub-Committee Wed, 3/21/2018, 7:15 PM; 07/03/2018 – Rhode Island DoA: Cumberland Finance Sub-Committee Wed, 3/7/2018, 6:15 PM; 27/03/2018 – Rhode Island DoA: Cumberland School Committee Tue, 3/27/2018, 6:00 PM; 06/03/2018 Cumberland Consulting Group Names Tom Howard Partner
Among 2 analysts covering Endurance Intl Gr Hldgs (NASDAQ:EIGI), 1 have Buy rating, 0 Sell and 1 Hold. Therefore 50% are positive. Endurance Intl Gr Hldgs had 2 analyst reports since October 26, 2018 according to SRatingsIntel. The firm earned “Outperform” rating on Friday, October 26 by Credit Suisse. The rating was downgraded by Oppenheimer to “Perform” on Wednesday, November 7. See Endurance International Group Holdings, Inc. (NASDAQ:EIGI) latest ratings:
07/11/2018 Broker: Oppenheimer Old Rating: Outperform New Rating: Perform Downgrade
26/10/2018 Broker: Credit Suisse Old Rating: Outperform New Rating: Outperform Old Target: $10 New Target: $11 Maintain
Investors sentiment increased to 2.17 in 2018 Q3. Its up 0.74, from 1.43 in 2018Q2. It is positive, as 0 investors sold Cumberland Pharmaceuticals Inc. shares while 6 reduced holdings. 3 funds opened positions while 10 raised stakes. 4.12 million shares or 0.05% less from 4.12 million shares in 2018Q2 were reported. 1,000 are held by Sei Investments. Dimensional Fund Advsr Limited Partnership has invested 0% of its portfolio in Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX). State Street accumulated 14,044 shares. Fincl Bank Of New York Mellon reported 0% stake. Prudential Fincl holds 0% or 29,800 shares. 97,733 are held by Acadian Asset Limited Liability. 381,471 were reported by Renaissance Techs Ltd. Fincl Bank Of America Corporation De owns 657 shares. Huntington Bank invested 0% of its portfolio in Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX). Bard, Illinois-based fund reported 79,115 shares. 260,730 were reported by Ny State Common Retirement Fund. Macquarie Ltd invested in 0% or 5,718 shares. Geode Mgmt Lc accumulated 48,610 shares. Royal Bankshares Of Canada holds 0% or 2 shares. Blackrock Inc holds 316,232 shares.
Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on acquiring, developing, and commercializing branded prescription products for hospital acute care and gastroenterology markets in the United States and internationally. The company has market cap of $87.89 million. It marketed products include Acetadote injection for the treatment of acetaminophen poisoning; Caldolor (ibuprofen) injection for the treatment of pain and fever; Kristalose (lactulose) for oral solution, a prescription laxative; Vaprisol (conivaptan) injection for treating hyponatremia; Omeclamox-Pak for the treatment of H. pylori infection and duodenal ulcer disease; and Ethyol (amifostine) for injection to treat oncology patients. It currently has negative earnings. The company’s product candidates in Phase II clinical trials comprise Hepatoren (ifetroban) injection for the treatment of hepatorenal syndrome; Boxaban (ifetroban) oral capsule for the treatment of aspirin-exacerbated respiratory disease; Vasculan (ifetroban) oral capsule for the treatment of systemic sclerosis; and Portaban for the treatment of portal hypertension.
More notable recent Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) news were published by: Nasdaq.com which released: “Cumberland Pharmaceuticals Sees Hammer Chart Pattern: Time to Buy? – Nasdaq” on January 25, 2019, also Seekingalpha.com with their article: “Cumberland Pharmaceuticals: One Step Forward Isn’t Enough – Seeking Alpha” published on December 28, 2018, Streetinsider.com published: “Theravance Biopharma (TBPH) to Sell VIBATIV to Cumberland Pharmaceuticals (CPIX) – StreetInsider.com” on November 06, 2018. More interesting news about Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) were released by: Nasdaq.com and their article: “Ocular (OCUL) Submits an sNDA for Eye Pain Drug Dextenza – Nasdaq” published on January 11, 2019 as well as Seekingalpha.com‘s news article titled: “Cumberland Pharmaceuticals Inc. 2017 Q4 – Results – Earnings Call Slides – Seeking Alpha” with publication date: March 07, 2018.
Since August 28, 2018, it had 1 insider purchase, and 0 sales for $2,400 activity. 400 shares were bought by Bonner Michael, worth $2,400 on Tuesday, August 28.
Endurance International Group Holdings, Inc., together with its subsidiaries, provides cloud platform solutions for small-and medium-sized businesses worldwide. The company has market cap of $1.07 billion. It offers Web hosting services, including entry-level shared hosting, and virtual private server and dedicated hosting solutions; Website building tools that enable subscribers with varying degrees of technical sophistication to create a Web presence; domain registration, management, and resale services; malware protection solutions to protect subscribersÂ’ Websites from viruses, malicious code, and other threats; and backup control solutions that enable subscribers to schedule, maintain, manage, and restore backups of their online data and Websites to meet their particular business needs, as well as Mojo Marketplace, online marketplace for WordPress themes, plugins, and other digital goods. It has a 248.33 P/E ratio. The firm also provides solutions that allow subscribers to have their Websites rendered on mobile devices; search engine optimization and marketing solutions; tools and services that enable subscribers to communicate with their clients and potential clients through social networks; and control panels and dashboards that enable subscribers to analyze activity on their Websites, optimize the impact of their Web presence design, and marketing campaigns.
The stock increased 0.81% or $0.06 during the last trading session, reaching $7.45. About 168,911 shares traded. Endurance International Group Holdings, Inc. (NASDAQ:EIGI) has declined 3.68% since February 15, 2018 and is downtrending. It has underperformed by 3.68% the S&P500. Some Historical EIGI News: 18/05/2018 – ENDURANCE INTERNATIONAL GROUP – REACHED AGREEMENTS IN PRINCIPLE TO SETTLE CERTAIN PURPORTED CLASS ACTION SECURITIES LAWSUITS PENDING AGAINST CO; 27/03/2018 – Study Finds Impact on Endurance Athlete Performance with Electric Field-Generating Compression Garments; 17/04/2018 – The National Trust For Scotland Foundation USA Annual Gala Honored Two Great Scots: Endurance Athlete, Broadcaster, and Philanthropist Mark Beaumont BEM and Architect Charles Rennie Mackintosh; 18/04/2018 – ClinicalTrial US: Effects of Inspiratory Muscle and Endurance Training in Heart Failure Patients With Pacemaker; 01/05/2018 – Endurance Intl Group 1Q Cash Flow From Ops $52.4 Million; 02/05/2018 – Yield Endurance Strategic Partner Closes on Initial Loan of 110 Bitcoins; 21/04/2018 – DJ Endurance International Group Holdi, Inst Holders, 1Q 2018 (EIGI); 18/05/2018 – ENDURANCE TECHNOLOGIES – FOR PERIOD FROM 1ST OCTOBER, 2017 TO 31ST MARCH, 2018 CO EXPECTS TO GET ELIGIBILITY CERTIFICATE IN DUE COURSE; 06/04/2018 – ClinicalTrial US: Relationship of Deep Cervical Flexor Muscle Endurance With Neck Position Sense and Body Balance; 12/03/2018 ClinicalTrial US: Protein Supplementation and Endurance Exercise Adaptations
More notable recent Endurance International Group Holdings, Inc. (NASDAQ:EIGI) news were published by: Globenewswire.com which released: “Endurance International Group to Announce 2018 Fourth Quarter and Full Year Financial Results on February 7, 2019 – GlobeNewswire” on January 17, 2019, also Bizjournals.com with their article: “Mass. lawmaker to file bill this week requiring women on corporate boards – Boston Business Journal” published on January 17, 2019, Nasdaq.com published: “WIX Stock Looks like It Could Be a Great Buy on the Dip – Nasdaq” on October 11, 2018. More interesting news about Endurance International Group Holdings, Inc. (NASDAQ:EIGI) were released by: Globenewswire.com and their article: “Endurance International Group Reports 2018 Third Quarter Results – GlobeNewswire” published on October 25, 2018 as well as Globenewswire.com‘s news article titled: “Endurance International Group to Announce 2018 Third Quarter Financial Results on October 25, 2018 – GlobeNewswire” with publication date: October 04, 2018.
